-
公开(公告)号：US20230348559A1
公开(公告)日：2023-11-02
申请号：US17996966
申请日：2021-04-23
IPC分类号： C07K14/725 , C12N5/0783 , C12N15/86 , A61K39/00 , A61P35/00 , A61P31/00 , A61K45/06
CPC分类号： C07K14/7051 , C12N5/0636 , C12N15/86 , A61K39/4611 , A61K39/4632 , A61P35/00 , A61P31/00 , A61K45/06 , C12N2510/00 , C12N2740/10043 , C12N2740/15043 , C12N2501/515 , A61K2239/55
摘要： The present disclosure relates generally to polypeptide constructs, and particularly relate to T-cell receptor (TCR) constructs having binding affinity for a specific cognate antigen. The disclosure also provides compositions and methods useful for producing such constructs as well as methods for the diagnosis, prevention, and/or treatment of conditions associated with cells expressing the cognate antigen recognized by the polypeptide constructs.
-
公开(公告)号：US12115192B2
公开(公告)日：2024-10-15
申请号：US18429758
申请日：2024-02-01
发明人： Cynthia Bamdad , Benoit Smagghe
CPC分类号： A61K35/17 , A61K39/4611 , A61K39/4631 , A61K39/46447 , A61P35/00 , C07K16/3092 , A61K2239/13 , A61K2239/17 , A61K2239/21 , A61K2239/49 , A61K2239/54 , A61K2239/55
摘要： Disclosed herein are chimeric antigen receptors (CARs) that target MUC1*. In some embodiments, the CARs have been optimized to reduce T cell exhaustion.
-
公开(公告)号：US20230405117A1
公开(公告)日：2023-12-21
申请号：US18252005
申请日：2021-11-05
CPC分类号： A61K39/4611 , A61K39/4631 , A61K2239/55 , A61K35/17 , A61P35/00 , A61K39/464482
摘要： Aspects of the present disclosure are directed to methods for classification and treatment of small cell lung cancer (SCLC). Certain aspects pertain to treatment of a subject having SCLC using a targeting agent for a cell surface protein, where a targeting agent is selected based on a subtype classification of the SCLC. Disclosed are methods for identifying a subject as having an SCLC subtype (e.g., SCLC-A, SCLC-N, SCLC-P, SCLC-I) and administering a targeting agent configured to target a cell surface protein associated with the identified SCLC subtype. Also disclosed are compositions comprising targeting agents for treatment of SCLC.
-
公开(公告)号：US20240261331A1
公开(公告)日：2024-08-08
申请号：US18429758
申请日：2024-02-01
发明人： Cynthia Bamdad , Benoit Smagghe
CPC分类号： A61K35/17 , A61K39/4611 , A61K39/4631 , A61K39/46447 , A61P35/00 , C07K16/3092 , A61K2239/13 , A61K2239/17 , A61K2239/21 , A61K2239/49 , A61K2239/54 , A61K2239/55
摘要： Disclosed herein are chimeric antigen receptors (CARs) that target MUC1*. In some embodiments, the CARs have been optimized to reduce T cell exhaustion.
-
5.发明公开公开(公告)号：US20240245721A1
公开(公告)日：2024-07-25
申请号：US18558882
申请日：2022-05-05
IPC分类号： A61K35/17 , A61K9/16 , A61K39/00 , C07K14/725 , C07K16/32
CPC分类号： A61K35/17 , A61K9/1647 , A61K39/4611 , A61K39/4631 , A61K39/464406 , C07K14/7051 , C07K16/32 , A61K2239/13 , A61K2239/29 , A61K2239/49 , A61K2239/55 , C07K2317/31 , C07K2317/53 , C07K2317/622 , C07K2319/03
摘要： Disclosed are chimeric antigen receptor (CAR) engineered T lymphocyte membrane coated nanoparticles (CAR-T MNP) compositions and methods of using the same for delivering therapeutics to a particular target.
-
6.发明公开公开(公告)号：US20240207318A1
公开(公告)日：2024-06-27
申请号：US18555513
申请日：2022-04-19
发明人： Rafael Cubas , Frederick G. Vogt , Yongliang Zhang
IPC分类号： A61K35/17 , A61K38/20 , A61K39/00 , A61P35/00 , C07K16/28 , C07K16/30 , C12N5/0783 , C12N15/86
CPC分类号： A61K35/17 , A61K38/2013 , A61K39/4611 , A61K39/4631 , A61K39/464411 , A61P35/00 , C07K16/2827 , C07K16/30 , C12N5/0638 , C12N15/86 , A61K2239/13 , A61K2239/17 , A61K2239/21 , A61K2239/22 , A61K2239/55 , C12N2740/10043 , C12N2740/15043
摘要： The present invention provides compositions comprising chimeric receptors, including chimeric costimulatory receptors (CCRs), and/or chemokine receptors, methods for preparing CCRs and/or chemokine receptors, and therapeutic populations of tumor infiltrating lymphocytes, marrow infiltrating lymphocytes, and peripheral blood lymphocytes expressing CCRs and/or chemokine receptors with increased therapeutic performance and other advantages for the treatment of cancers, including solid tumor cancers.
-
公开(公告)号：US20240009241A1
公开(公告)日：2024-01-11
申请号：US18251881
申请日：2021-11-04
发明人： Patrick HWU , Cassian YEE , Geogory LIZEE
CPC分类号： A61K35/17 , A61K45/06 , A61K39/4632 , C12N5/0636 , A61K39/4611 , C07K16/2863 , A61K39/464404 , A61P35/00 , A61K2239/28 , A61K2239/55
摘要： This disclosure provides for engineered T cell Receptors (TCRs), cells comprising the TCRs, and methods of making and using the TCRs. The current disclosure relates to TCRs that specifically recognize EGFR neoantigens comprising L858R mutations and restricted to HLA class I A31 and A33 allotypes. Accordingly, aspects of the disclosure relate to a polypeptide comprising an antigen binding variable region comprising the amino acid sequence of a CDR3 of the disclosure or an amino acid sequence with at least 80% sequence identity to a CDR3 of the disclosure. Further aspects relate to an engineered T-cell Receptor (TCR) comprising a TCR-b polypeptide and a TCR-a polypeptide, wherein the TCR-b polypeptide comprises an amino acid sequence of a CDR3 of the disclosure or an amino acid sequence with at least 80% sequence identity to a CDR3 of the disclosure and the TCR-a polypeptide comprises the amino acid sequence of a CDR3 of the disclosure or an amino acid sequence with at least 80% sequence identity to a CDR3 of the disclosure.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.009 秒)
